Figure 4
From: Belatacept inhibit human B cell germinal center development in immunodeficient mice
Belatacept treatment affect the plasma cells’ ability to secrete immunoglobulins. Intrasplenic injection of NSG mice were realize with 10 × 106 of CD8 depleted PBMCs (CD8-). Belatacept (5 mg/kg) were injected either at the same day of cells injection (B0) or day 12 (B12) Untreated mice (NT) served as control group. (A) Serum of mice were collected at day 21 and human immunoglobulin, IgG (1, 2, 3 and 4), IgA, IgE, and IgM were analysis by Luminex assay. The cumulative data of five independent experiments are shown. Each point represents a single xenograft; data are presented as mean percentage ± SEM. Statistical significance from the controls (NT) was determined using one-way anova test and Tukey’s multiple comparisons test. p ≤ *0.05, **0.01, ***0.001 and ****0,0001. (B) Pie chart of IgGs repartition between complement binding IgGs (IgG1, IgG3) and non complement binding IgGs (IgG2,IgG4) for the three groups.
